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Abstract
Marginal zone lymphoma (LMZ) accounts for 5–15% of all NHL in Europe. 
This option includes splenic (0.7%), nodal (2.4%) and extranodal (MALT-Mucosa-
Associated Limphoid-Tissue) LMZ −5%. Extranodal variants of MALT lymphomas 
can occur in any organ due to chronic antigenic stimulation. The most frequent 
localization associated with Helicobacter pylori (Hp) infection is the stomach - 30%. 
The gastrobiopsy material of 115 patients with lymphoid cell infiltrates in the 
gastric mucosa was studied, a complex of morphological diagnostic criteria for 
MALT gastric lymphoma for gastrobiopsy was developed based on a combination of 
histological and immunohistochemical characteristics of tumor cells, the nature of 
their growth. It is known that the mandatory initial therapy for local stages of Hp-
positive MALT lymphoma of the stomach is the eradication of Hp. 68 patients with 
stages I – II of gastric MALT lymphomas were observed. Anti Hp therapy resulted 
in 87.8% of complete remissions, with a median duration of 51 months. The median 
time to the onset of Hp-eradication was 3 months, and the median time to the 
implementation of the antitumor process was 5.5 months. With a median follow-
up of 58 months, the median overall and relapse-free survival was not achieved: 
10-year OS - 100%, 10-year RFS - 92. 3%.
Keywords: MALT lymphoma, stomach, gastrobiopsy, morphology, 
immunohistochemistry, anti-Helicobacter pylori therapy
1. Introduction
Mucosa-associated lymphoid tissue (MALT) lymphoma is an indolent extrano-
dal marginal zone B-cell lymphoma, originating in acquired MALT that is induced 
in mucosal barriers as part of a normal adaptive immune response to a chronic 
immunoinflammatory stimulus, most notably chronic infection by Hp [1].
MALT lymphomas can show a wide morphologic spectrum. MALT gastric 
lymphoma is characterized by mature cellular elements, the presence of lymphoid 
follicles and lymphoepithelial lesions (LELs) [2]. Histological diagnosis of MALT 
lymphoma of the stomach is rather difficult and is made basing on a combination 
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of morphological features because none of them is exclusively pathognomic for this 
lymphoma type [3, 4]. Immunohistochemical analysis is much importance in the 
diagnosis of MALT-lymphoma, especially in controversial cases [5–7].
In recent years, the principles of MALT lymphoma treatment have been defined. 
According to the recommendations of the European Society of Medical Oncologists 
(ESMO), at the first stage of treatment of patients with Hp + MALT gastric lym-
phoma, regardless of the stage, it is recommended to prescribe anti-Hp eradica-
tion therapy. However, there is an addition in the guidelines of the general cancer 
network. According to the addition Eradication Antibiotic Therapy is preferable for 
patients with stages I and II1 according to Lugano, in the absence of translocation 
t(11; 18), which is found in 15-40% of patients with gastric MALT lymphoma and is 
a predictor of refractoriness to antibiotic therapy. These patients with translocation 
t(11, 18) should in any case receive additional treatment. Alternatively, rituximab 
alone or radiation therapy can be used.
As an antibacterial anti-Hp therapy, a 3-component regimen is usually used: a 
proton pump inhibitor with clarithromycin, in combination with amoxicillin or 
metronidazole for 10-14 days. The effect should be confirmed morphologically 
6 weeks after eradication therapy and at least 2 weeks after discontinuation of the 
proton pump inhibitor.
Patients with a widespread tumor process - more than stage IIe require a system-
atic approach in the presence of indications for therapy.
2.  Part 1. Morphoimmunological aspects of the diagnosis of MALT 
gastric lymphomas
2.1 Materials and methods
The study was performed on gastrobiopsies from 115 patients with lymphoid cell 
infiltration of gastric mucosa including 71 patients with MALT lymphoma of the 
stomach, 23 patients with reactive (nontumor) lymphoid infiltrations, 21 patients 
with non MALT type peripheral small B-cell gastric lymphomas (cytological grade 
I or I–II FL, MCL), Burkitt’s lymphoma (BL). There were 48 males and 67 females 
in the study group. The study was carried out using histological and immunohisto-
chemical methods. Immunohistochemical study was performed on cryostatic and 
paraffin sections. The reaction was assessed using fluorescent microscopy. Table 1 
shows the antibodies that were used to stain the preparations.
Antibody Application Manufacturer
CD19, CD20, CD37 antibodies to linear antigens of 
B-lymphocytes
DAKO
CD3, CD4, CD5, CD7, CD8 antibodies to linear antigens of 
T-lymphocytes
DAKO
CD38 determination of plasma cells DAKO
CD21 и CD23 determination of follicular dendritic cells DAKO
HLADR, CD10 lymphoid progenitor cells, granulocytes DAKO
immunoglobulin classes D, G, M Ig expression DAKO
light chains of immunoglobulins λ и κ. determination of clonality DAKO
Table 1. 
List of antibodies used.
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2.2 Morphoimmunological characteristics of MALT lymphoma
The study was performed in 71 patients aged 14 to 83 years, mean age 54.32 years. 
MALT lymphoma is always accompanied by active chronic inflammation which in 
half of cases is associated with H. p. infection; mucosal defects are found in two 
thirds of cases. MALT lymphoma has a very polymorphous morphological picture 
due to heterogeneous composition of the tumor component and a great interpatient 
variability of combinations. We assessed the following histological signs:
1. Cell composition with respect to nucleus shape;
2. The presence of monocytoid B-lymphocytes;
3. The presence of plasma cells;
4. The presence of tumor cell plasmocytoid differentiation;
5. LELs;
6. The presence of follicles (reactive, colonized);
7. The presence of blasts.
2.2.1 Cellular composition according to the shape of the nuclei of lymphoid cells
1. Cells with mainly round nuclei (morphologically closest to small lymphocytes: 
with clearcut nucleus outline, highly dispersed chromatin, non-visualized 
nucleoli, cytoplasm looking like a narrow, poorly outlined rim) — 5 cases 
(7.04%) (Figure 1).
2. Cells with centrocytoid morphology (small cells with cleaved or wedge-like 
nuclei, moderately dispersed or granulated chromatin, invisible nucleoli and a 
moderately wide cytoplasm rim) — 7 cases (9.86%).
3. Cells with mixed morphology (round and centrocytoid nuclei) — 53 cases 
(74.65%).
4. Cells with irregular nuclei — 6 cases (8.45%).
2.2.2 Tumor cell size
Tumor cell size ranged from small, similar to small lymphocytes to medium, 
similar to prolymphocyte and twofold greater than small lymphocytes. All MALT 
lymphomas were conventionally divided into 3 histological groups depending on 
the size of tumor cells (Table 2). The larger were the cells the greater were their 
degree of atypia and similarity to blasts.
2.2.3 Cell elements with a different morphology
Cell elements having a different morphology were present in the tumor infiltra-
tions in parallel with the predominant type (Table 3).
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Monocytoid B-lymphocytes (35,2%). They were with a bean-shaped or irregular 
nuclei, wide and poorly stained cytoplasm.
Plasma cells (85,9%). In most cases plasma cells were located immediately under 
covering epithelium as a massive sheet (46.47%), or less frequently were dispersed 
in small portions in surface layers of gastric proper mucous plate among leukocytes 
Morphological sign small cells  
(n = 26)
small and medium 
cells (n = 40)
medium cells 
(n = 5)
Monocytoid B-lymphocytes n − 22 (84,6%)
e −4 (15,4%)
n − 24 (60%)
y − 16 (40%)
n − 1
y − 4
Plasma cells n-1 (3,9%)
s − 7 (26,9%)
m − 18 (69,2%)
n-7 (17,5%)





Cells with plasmocytoid 
differentiation
32% 18,2% 20%
Lymphoepithelial lesions n − 12 (46,2%)
y − 14 (53,8%)
n − 23 (57,5%)
y - 17 (42,5%)
n - 1
y - 4
Reactive follicles-colonized n-18 (69,2%)
y − 7 (30,8%)
c − 18 (37,5%)
n − 29 (72,5%)
y − 11 (27,5%)




Blasts n − 15 (57,7%)
y − 11 (42,3%)
s − 81,8%
n − 4 (10%)





Note: n - no, y- yes, s- single, m-multiple, c-colonized, l- layers of blast more than 20.
Table 3. 
MALT-lymphoma: Morphological characteristics of lymphoid cell infiltration with respect to three groups.
Figure 1. 
Cytological features of MALT lymphoma can range from small lymphocytic (b) morphology to monocytoid  
(a, c) morphology (hematoxylin–eosin, original magnifications ×400 [2].
Cell nucleus shape Small cells  
(n = 26)
Small and medium cells  
(n = 40)
Medium cells  
(n = 5)
round 4 (15,4%) 1 (2,5%) 0
round /centrocyt-like 17 (65,4%) 35 (87,5%) 1
centrocyt-like 5 (19,2%) 1 (2,5%) 1
irregular 0 3 (7,5%) 3
Table 2. 
MAL lymphoma: Cell element morphology of lymphoid infiltration with respect to three groups.
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(39.43%). The plasma cells had typical appearance: nuclei, more frequently of a 
round or slightly irregular shape, wide cytoplasm in the form of a rim or a tongue of 
flame of intense pink color after Brachet staining.
Cells with plasmocytoid differentiation (21,13%). They resembled plasma cells, 
that was better observed after Brachet staining.
Lymphoepithelial lesions (LELs) as aggregations of 3 or more marginal zone 
cells destroying glandular epithelium were found in 50,7%. 6 cases (17.14%) 
presented with ‘blast’ LELs formed by large blasts (Figure 2).
Follicles or follicle-like structures with light-color proliferation centers consisting 
of centrocytes and centroblasts, a small number of mitotic figures and individual 
macrophages with cellular detrite in their cytoplasm were present in 14,09% cases. 
Proliferation centers could be surrounded by a partially preserved, thin mantle zone. 
Lymphoid follicle colonization when preexisting lymphoid follicle was replaced by 
small neoplastic cells was found practically in half the cases with follicles (15,49%).
Blasts. They were with either roundIoval/slightly irregular nuclei and 1 to 
3 nucleoli, or with round bottle-shape nuclei and 1 compact, centrally located 
nucleolus. Amount of large blast cells varies from single cells to small group of cells 
(not more than 20 cells in one group).
2.3 Immunophenotyping of MALT- lymphoma
49 cases were analyzed. MALTI-ymphoma neoplastic elements were free from 
characteristic pathognomic immunological signs.
1. CD45 - common leukocyte antigen. There was a positive monomorphic reaction 
with diffuse growth of infiltrate. Cells, less frequently expressing this antigen, 
formed large clusters among the glands
2. B-cell markers (CD19, CD20). The infiltration cells expressed pan-B-cell 
markers as diffused, dense positive staining in most cases or, less frequently, 
as follicle-like areas on positive cell groups.
3. CD5 – antigen. Tumor cells were CD5-negative in all cases.
4. T-cell markers (CD8, CD4). T-cell component was present in most cases as 
single diffused cells, with CDI8 cytotoxic lymphocytes slightly predominating 
over CD4-helpers.
Figure 2. 
Lymphoepithelial lesions (LELs) as aggregations of 3 or more marginal zone cells destroying glandular 
epithelium.
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5. CD23 marker. Tumor cell reaction with CD23 was negative in more than 90% 
of cases.
6. CD21 and CD23 markers. FDCs were found in 19 cases. They formed a network 
among CD23-negative cells of tumor infiltration, though more frequently  
(17 cases, 89.47%) looked as loose clusters in CD21-positive infiltration 
(5 cases) or in CD21-negative infiltration (12 cases).
7. CD38 marker was assessed on both tumor cells and plasma cells. The tumor 
cell reactivity was negative; CD38- positive plasma cells were located in surface 
mucosa as foci or layers.
8. CD10 marker. All cases were CD10-negative.
Expression of CD20, CD3, IgD, IgG, IgM, and Ig λ and κ light chains was studied 
in 35 paraffin sections:
• clear-cut CD20 expression on tumor infiltration cells was found in all cases.
• CD3 was expressed on single diffuse cells among B-cells.
• Ig of all three classes were expressed on plasma cells.
• tumor cells demonstrated no Ig expression.
• Ig λ and κ light chains were expressed on plasma cells and very weakly 
on lymphoid neoplastic cells, though restriction of one of the chains was 
not found.
Therefore, all paraffin sections demonstrated plasma cell polyclonality, i.e. 
expression of different classes of Ig without restriction of one of the chains.
2.4  Differentiation criteria in the diagnosis of MALT-lymphoma of the stomach 
and morphologically similar lesions
2.4.1 Reactive lymphoid infiltrations of the stomach
The study was performed in gastrobiopsies from 23 cases aged 18 to 85 years, 
mean age was 53.47 years. More than half (56.52%) of the gastrobiopsies dem-
onstrated mucosal defects of different severity: from surface erosion to ulcer. All 
23 cases had signs of active chronic inflammation, mainly of moderate or severe 
degree (39.13 and 56.52% respectively). Twenty two (95.65%) cases presented with 
Helicobacter pylori in mucosa or in gland lumens on epithelial surface, the degree of 
contamination correlating with inflammation activity.
2.4.1.1 Tumor cell size
Lymphoid cells of the studied infiltrates were predominantly small (86.96%). 
There were no infiltrations consisting of medium-sized cells among the cases 
studied.
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2.4.1.2 Cellular composition according to the shape of the nuclei of lymphoid cells
Morphological signs of reactive lymphoid cell infiltrates were as follows: cells 
with centrocytoid morphology of nuclei, without signs of cytological atypia, or 
with mild cytological atypia, predominated.
2.4.1.3 Cell elements with a different morphology
1. Monocytoid B-lymphocytes were not detected in any of the investigated  
infiltrates.
2. Plasma cells in all 23 cases were found in large numbers in the form of layers 
under the surface integumentary epithelium.
3. Cells with plasmacytoid differentiation were not found.
4. Lymphoepithelial lesions were present in about 1/5 of cases. LELs consisted of 
more than 3 small lymphoid cells, and the glands were distorted. Infiltration 
of the epithelium of the glands with segmented leukocytes or so called crypts 
of abscesses were mainly observed.
5. Follicles were found in 34,78% of samples as round or slightly irregular,  
light-color centers of proliferation with a typical centrocyte or centroblast 
composition and single macrophages with wide cytoplasm and phagocyted 
bodies. Germinal centers were surrounded by a narrow, denser and darker 
(after hematoxylin and eosin staining) mantle zone of small lymphoid cells 
with round nuclei. There were no cases with follicle colonization.
6. Two (8.7%) cases presented with single large (blast) cells. These cells 
looked like centroblasts or immunoblasts and were diffused in small cell 
infiltration.
2.4.1.4 Immunophenotyping of reactive lymphoid infiltrates
1. CD45 marker. A positive reaction was detected on all cells of the infiltrate, 
which were mainly in the form of small groups or loose diffuse clusters.
2. T, B-cell markers (CD19, CD20, CD8, CD4). There was a mixed cell infiltrate, 
where T-lymphocytes predominated over B-lymphocytes, or less often were in 
equal proportions, while CD8-positive T-lymphocytes predominated.
3. CD21, CD23, CD5, CD10. There was a negative reaction of infiltrate cells.
4. When reacting with CD21 and CD23, the presence of a positive, well-expressed, 
arranged network of FDC reactive follicles was noted.
5. CD38 - marker. Expression on plasma cells was noted.
To sum up, majority cases of reactive infiltrates have mild cytology atypia, 
severe atypia cases were not found at all, monocytoid B-cells were absent, and 
lymphoid cells did not undergo plasmocytoid differentiation.
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Thereby, lymphoid infiltrate of MALT-lymphoma, in contrast to reactive 
infiltrate, has tendency to be more destructive and expansive. One third of all the 
MALT-lymphoma cases has mild cytology atypia. As cytological atypia grows, 
monocytoid cells appear more frequently, amount of plasma cells progressively 
decrease, moreover, the frequency of follicle appearance decrease, while the 
majority of cases have follicle colonization.
2.4.2 Peripheral small B-cell lymphoma of the stomach
The study was performed in 21 cases aged 14 to 83 years, mean age was 48 years. 
The cases were represented by follicular lymphoma of I, I – II, II cytological degree 
(n = 10), lymphoma from cells of the mantle zone (n = 6), Burkitt’s lymphoma 
(n = 5). Defects of the mucous membrane from surface erosion to ulcer were noted 
in two-thirds of the material examined. Inflammation was mild or moderate in 
all variants of lymphomas. Helicobacter pylori infection was observed in 8 cases 
(38.1%). Infiltration growth was focal diffuse in about a third of cases with mantle 
cell lymphoma and follicular lymphoma, and diffuse in 2/3 of cases. In Burkitt’s 
lymphoma the infiltration growth was diffuse in all 5 cases. Burkitt’s lymphoma 
consists of cells of medium size, but it can be misinterpreted as small cell lymphoma 
due to artificial deformation after the tissue fixation. Morphological characteristics 
of follicular lymphoma, lymphoma from cells of the mantle zone, Burkitt’s lym-
phoma are compared in Table 4.
Thereby, morphological features, typical for MALT-lymphoma (atypical lym-
phoid small cells, reactive follicles, LELs) can be seen in other peripheral B-cell 
lymphomas, that is why ICH-research is decisive.
Among peripheral small-cell B-cell lymphomas, 7 cases of follicular lym-
phoma and 4 cases of mantle cell lymphoma were studied by immunohistochem-
istry. All studied lymphomas (lymphoma from cells of the mantle zone, follicular 
lymphoma) were B-cells and contained single or small groups of diffuse T-cells. 
In this case, the diagnosis of follicular lymphoma was made on the basis of the 
totality of CD23, CD38, CD10 occurring in various combinations. It should be 
noted that all 3 cases of gastric follicular lymphoma were CD10-negative, while 
the cells of the tumor infiltrate were either CD38-positive or CD23-positive. For 
lymphoma from cells of the mantle zone the reaction with CD5 was diagnostically 
significant: all cases were positive. Morphological characteristics of lymphoid 
cell infiltrations in gastric mucosa for lymphomas and reactive infiltrations are 
compared in Table 5.
Morphological sign Follicular 
lymphoma (n = 10)
Lymphoma from cells of 
the mantle zone (n = 6)
Burkitt’s 
lymphoma (n = 5)
Tumor cell size small cells small and medium medium cells
Monocytoid B-lymphocytes 1 1 0
Plasma cells 7 2 0
Cells with plasmocytoid 
differentiation
1 0 0
Lymphoepithelial lesions 4 1 2
Reactive follicles-colonized 2 0 0
Blasts 9 4 5
Table 4. 
Peripheral small B-cell lymphomas, Burkitt’s lymphoma: Morphological characteristics of lymphoid cell 
infiltration in gastric mucosa.
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3. Part 2. Clinical aspects of MALT gastric lymphomas
3.1 Materials and methods
Blokhin National Medical Research Center of Oncology analyzed the data of 68 
patients with early stages of gastric MALT lymphoma who received initial treatment 
from 1973 to 2004 [8]. The median follow-up was 61 months. The prevalence of 
female patients was noted - 64.71% versus 35.29%, almost half of the patients - 
48.7% were over 60 years old. In accordance with the criteria for dividing gastric 
MALT lymphomas into categories depending on the number and nature of growth 
of blast-transformed cells, the patients were distributed as follows: small cell sub-
variant - 31 (45.6%); intermediate - 22 (32.4%) and mixed - 15 (22.0%). H. pylori 
infection was found in 54 patients - 85.7%.
A comprehensive assessment of the effectiveness of therapy consisted in sum-
marizing clinical, morphoimmunological, radiological, ultrasound and endoscopic 
data. To assess the long-term results, the indicators of the duration of the delaying 
time to relapse, event-free and overall survival were used. To determine the reliabil-
ity of the results obtained, the X-2 criterion and the Student’s test were used to plot 
the survival curves - according to the Kaplan and Meier method, the comparison of 
the curves was performed using the Lograng test.
3.2 Analysis of clinical characteristics
A comparative analysis of the clinical characteristics of 3 groups of patients was 
carried out according to morphological variants, which made it possible to identify 
the clinical features of each of them (Table 6):
• For small-cell gastric MALT lymphomas, the most characteristic was the pre-
dominance of women, elderly age (63 years), the presence of a long gastroen-
terological history, scant clinical symptoms, an isolated lesion of the stomach 
body with a predominance of ulcerative and gastritis-like macroscopic growth, 
stage I of the disease and the presence of Helicobacter pylori infection
• For the intermediate subvariant of gastric MALT lymphoma, the prevalence of 
women is also characteristic, the median age is 61 years, the rapid development 
of the disease (within 1 year), early onset of intense pain syndrome, a more 
pronounced tendency to the spread of the tumor in the stomach (larger lesion 




Other lymphomas (FL, MCL)
Monocytoid B-lymphocytes 35,2% Absent FL −10%, MCL – 16,6%
Plasma cells 85,9% 100% FL −70%, MCL – 33,3%
Cells with plasmocytoid 
differentiation
21,1% Absent FL −10%, MCL – 0%
Lymphoepithelial lesions 50,7% Single in 20% FL −40%, MCL – single in 16,6%
Reactive follicles-colonized 30% (15% - 
signs of col.)
30%, no signs  
of col.
FL - 20% with col.
MCL – 0%
Blasts 73,2% 10% FL - 90%MCL – 66,6%
Note: FL- follicular lymphoma, MCL- lymphoma from cells of the mantle zone, col- colonization.
Table 5. 
Diagnostically meaningful morphological characteristics.
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volume) and on adjacent organs and lymph nodes, the presence of Helicobacter 
pylori infection is detected in the form of a moderate degree of bacterial content.
• Mixed-cell gastric MALT lymphomas develop in young people (median - 
41 years), with intense permanent pain syndrome, with a predominance of 
infiltrative-ulcerative and ulcerative forms of growth, with a tendency to early 
spread to regional lymph nodes - by the time of diagnosis in 2 / 3 patients, stage 
II is detected, and Helicobacter pylori infection is observed in only half of the 
patients.
3.3 Treatment results depending on morphological subvariant
3.3.1 The immediate effectiveness of various therapies
Various approaches have been used in treating patients, including anti-
Helicobacter pylori therapy, surgery, and systemic chemotherapy. When using 
eradication antimicrobial therapy in the general population, the overwhelming 
majority of patients achieved a complete response (CR) - 87.5%, the median 
duration of CR - 51 months (range: 5 months - 81 months). The effect was 
realized quickly: the mediana of Hp eradication was 3 months, and the mediana 
of the CR observance was 5.5 months. Surgical treatment was performed for 28 
patients (41.12%).
The efficacy of the therapy, depending on the morphological subvariant was 
evaluated (Table 7).
The efficacy of treatment in the group of patients with small cell subvariant of 
gastric MALT lymphoma was evaluated in all 31 patients. The median follow-up 
in this group was 64 months. Eradication anti-Hp therapy, which was used as the 
only method of treatment only in stage I (Lugano classification, 1993) of small-cell 
gastric MALT lymphomas, was performed for 16 patients (51.6%).
This approach allowed achieving CR in the vast majority of patients - 14 
(87.5%), and the median duration of complete remissions was 51 months (5 - 
81 months). Thus, anti-Helicobacter pylori therapy is competent and effective in 
primary small-cell gastric MALT-lymphomas of stage I with H. pylori, i.e. positive 
tumors with limited tumor lesion of the stomach (stage I) (Figure 3a, b).
Characteristics Morphological variant of MALT lymphoma
Small cell Intermediate Mixed cell
Number of patients - 68 31 (45.6%) 22 (32.4%) 15 (22%)
Median age 63 61 41
Women (%) 67.7% 68.2% 53.3%
Duration of disease development up to 12 months 61.3% 100% 80%
Hp-infection 96.7% 90% 53.8%























Characteristics of patients with stage I-II gastric MALT lymphomas.
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In an earlier historical period (since 1973), 12 patients underwent surgical 
treatment of small-cell gastric MALT lymphomas: 11 patients underwent radical 
surgical treatment. The median duration of complete remissions in radically oper-
ated patients was 73 months (21 - 168 months), however, with a significant negative 
impact on the quality of life of patients.
The indication for chemotherapy (LVPP, COP, CHOP regimens) was the absence 
of H. pylori infection, while in all patients stabilization of the tumor process was 
only achieved. The efficacy of treatment in the group of intermediate subvari-
ant of gastric MALT lymphoma was evaluated in 22 patients. The majority - 14 
(63.7%) - received anthracycline-containing chemotherapy in combination with 
anti-Helicobacter pylori therapy. H. pylori eradication occurred in all patients within 
1 to 8 months (median - 3 months), and complete remissions were achieved in 10 
of them (71.4%). The median duration of CR was 37.5 months (1 - 53 months). 
Our experience of using induction standard chemotherapy in combination with 
anti-Hp-therapy for H. pylori, a positive MALT lymphoma of the intermediate 
subvariant, demonstrates a high frequency of achieving remissions and a stable 
long-term effect.
Radical surgical treatment was performed for 7 patients (31.8%): 2 - gastrec-
tomy, 5 - distal subtotal gastrectomy were performed. The median duration of CR 
was 50 months (2–96 months).
The efficacy of treatment of the mixed subvariant MALT gastric lymphoma was 
assessed in all 15 patients, most of whom underwent surgical treatment at one of 
phase of disease (12/15) and only three received systemic chemotherapy alone. The 
immediate results of treatment of mixed gastric MALT lymphoma were better in 7 
initially radically operated patients with subsequent adjuvant chemotherapy - the 
duration of CR was 57 months (mediana).










Small cell variant of gastric MALT lymphoma - 26 patients
anti-H.pyloi -therapy 87.5 51 12.5 — 16 – 51.6
Surgical 100 73 — — 12 – 38.7
Chemotherapy — — 100 — 3 – 9.7
Total 26 – 83.9 5 – 16.1 — 31 – 100
Intermediate variant of gastric MALT lymphoma - 22 patients
Chemotherapy  
+ anti-H.pyloi
71.4 37.5 7.1 — 14 – 63.7
Surgical 100 54 — — 8 – 46.3
Total 18 – 81.8 3 –13.6 — 1 – 4.6
Mixed subvariant of gastric MALT lymphoma - 15 patients
Surgical treatment 
+ PCT
11 57 — 1 (7%) 12-80
Chemotherapy 1 (7%) 39 1(7%) 1(7%) 3-20
Total 12- 80 — 1 (7%) 2 (13%) 15 – 100
Table 7. 
Direct efficacy of various types of therapy depending on the morphological subvariant of gastric MALT 
lymphomas.
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The results of standard anthracycline-containing chemotherapy turned out to 
be less impressive: out of 3 patients, complete remission at stage I of the process was 
achieved and persists for 39 months in 1 patient.
3.3.2 Relapses
With H. pylori - positive MALT gastric lymphomas of a small cell structure, out 
of 14 patients treated with antibiotics, relapse occurred only in 1 patient (7.1%) - 
7 months after the CR. In this group, among radically operated patients, relapses 
were detected in 3 cases (27.3%).
In the group of patients with an intermediate variant, who received fundamen-
tally different therapy (surgical treatment and systemic PCT (palliative chemo-
therapy)), the course of the disease was comparable in terms of the frequency of 
relapse: 30.0% and 37.5%, respectively. The difference is noted only in the timing 
of the detection of relapse: with conservative treatment, all relapses occurred in the 
first 2 years, and after surgical treatment later - in terms of 2 to 5 years (after 2, 3 
and 5 years).
Attention should be paid to the predominant development of local recurrence in 
the stomach, regardless of the type of treatment and the type of NHL.
With the mixed sub-variant MALT, no relapses were detected.
3.3.3 Long-term results
Survival rates were calculated for 5-year and 10-year periods, which is explained 
by the long period of observation of patients. The overall 5-year survival rate (OS) 
was 96.8% in the case of MALT lymphoma of the small-cell subvariant. The indica-
tors of 5-year OS are significantly lower with the intermediate subvariant - 71.4% 
(p = 0.008). These differences become even more pronounced to 10 years follow-up 
(Table 8). A small number of cases of mixed-type MALT lymphoma does not allow 
us to speak of significant differences.
The analysis of the influence of other characteristics on survival allowed us 
to establish that gender and age are not prognostically significant. Information 
about the further life of patients, depending on the methods of therapy used, is 
strategically important: a sparing conservative approach - anti-H. pylori antibiotic 
therapy - and an aggressive surgical method provide a high 5-year OS in the small 
Figure 3. 
a) Endoscopic findings in subject with Hp + MALT-lymphoma prior anti-Hp-therapy. b) -after anti-Hp-
therapy (from the archive of Malikhova O.A.).
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cell subvariant of gastric MALT lymphoma, but with a significant deterioration in 
the quality of life in using a surgical approach.
Comparison of the conservative (chemotherapy + anti-Helicobacter antibiotic 
therapy) approach with the surgical approach in the intermediate variant demonstrates 
that OS indicators are comparable only in the first year of observation and amount to 
83.8% and 80%, respectively; on the 3rd and 5th year of observation, the difference in 
these OS indicators increases by 25%: 81.8% and 55.8%, respectively. Disease-free sur-
vival is 15% higher with conservative therapy by the end of the first year (83.3% versus 
67.5% with surgical treatment). This means that surgery for an intermediate variant of 
MALT lymphoma does not provide long-term control of the disease.
The analysis of survival rates in mixed gastric MALT lymphoma was not 
performed due to insufficient number of observations. Thus, the analysis of 
long-term results confirmed the clinical, morphological and prognostic hetero-
geneity of this tumor, a favorable prognosis of primary MALT gastric lymphoma 
in general, and significant differences in survival in different morphological 
subvariants.
4. Discussion
Currently, according to practical recommendations, as a second-line treatment for 
patients in whom antibiotic therapy did not lead to remission, rituximab is prescribed 
as a monotherapy: 4 weekly administrations at a standard dose of 375 mg/m2 [9, 10].
In a study by G. Martineli, E. Zucca et al. 27 patients were enrolled exclusively 
with NHL gastric MALT lymphoma who received weekly rituximab injections [10]. 
In this work, the clinical activity of rituximab was confirmed in patients with gas-
tric MALT lymphoma, refractory to antibiotic therapy or without association with 
Helicobacter pylori: the overall response (OR) was 77%, CR - 46%. With a median 
follow-up of 33 months, only 2 relapses were detected - after 26 and 14 months.
The IELSG-19 study as of today is the largest randomized trial comparing 
rituximab + chlorambucil with chlorambucil alone, in which the combination has 
Morphological 
subvariant
N OS -Survival rate (%)
1 year 3 years 5 years 10 years
Overall survival
Small cell 31 96.8 ± 3.2 96.8 ± 3.2 
p = 0,00
96.8 ± 3.2 89.1 ± 0.6
Intermediate 22 85.7 ± 7.6 71.4 ± 9.9 71.4 ± 9.9 52.9 ± 13.6
Mixed 15 92.9 ± 6.9 85.7 ± 9.4 85.7 ± 9.4 85.7 ± 9.4
Disease-free survival (DFS) (%)
Small cell 25 92 ± 5.4 88 ± 6.5 88 ± 6.5 78.7 ± 8.5
Intermediate 16 80.2 ± 10.3 66.7 ± 12.2 59.3 ± 12.9 50.8 ± 13.5
Mixed 15 100 100 100 100
Event-free survival (EFS) (%)
Small cell 31 86.6 ± 6.2 79.7 ± 7.4 77.8 ± 8.2 68.7 ± 8.7
Intermediate 22 66.7 ± 10.3 52.4 ± 10.9 47.6 ± 10.9 28.2 ± 13.6
Mixed 15 86.7 ± 8.8 86.7 ± 8.8 80 ± 10.3 80 ± 10.3
Table 8. 
Long-term results of MALT lymphoma therapy depending on the morphological subvariant.
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shown the best results (OR) - 95% vs. 85%; CR - 79% vs. 63%). Based on data from 
this study (NCT 00210353) [11]. C. Thieblemont et al. the International Prognostic 
Index of Extranodal Lymphoma - MALT-IPI was developed [12]. Three factors were 
identified that influence event-free survival: age ≥ 70 years, Ann Arbor stage III 
or IV, and increased LDH levels. 5-year EFS in the low, intermediate and high risk 
groups was 70%, 56% and 29%, respectively.
The addition of rituximab to bendamustine provided significant advantages 
in a prospective study involving 60 patients with untreated extranodal MALT 
lymphoma: OR was 100, CR - 98%, 7-year EFS and PFS (progression-free survival) 
were 88% and 93%, respectively [13].
Fludarabine-containing regimens are excluded by most of the clinical recom-
mendations from treatment standards and NHL due to the increased risk of devel-
oping second tumors [14].
In August 2020, a new treatment option for MZL relapses was registered in the 
Russian Federation - the lenalidomide + rituximab (R2) regimen. The high efficacy of 
this combination compared to rituximab + placebo was confirmed in the AUGMENT 
study for phase III, involving 358 patients with recurrent/refractory follicular lym-
phoma (295 patients) and marginal zone lymphoma (63 patients): median PFS was 
39.4 months in the R2 group compared to 14.1 months in the placebo group [15].
The efficacy and safety of ibrutinib in relapses and refractory MZL was dem-
onstrated in a st median udy of phase II involving 63 patients, of which 32 (51%) 
with extranodal MALT lymphomas [16]. With a median follow-up of 19.4 months 
median response time was not reached, and PFS - 14.2 months (mediana).
Blockade of the phosphatidylinositol 3-kinase (PI3K) pathway seems to be a very 
promising direction in the treatment of relapses or refractory MZL. However, drugs 
from this group are currently not registered in the Russian Federation.
5. Conclusion
MALT gastric lymphoma is a variant of MZL with an indolent prognosis and 
long survival, but a high tendency to develop relapses over time.
Diagnosis and differential diagnosis of lymphoma is difficult and includes 
morphological and immunohistochemical analysis. In this study, morphoim-
munological criteria for the diagnosis of MALT gastric lymphoma and differential 
diagnosis with processes similar in histological picture (reactive infiltrates, periph-
eral small-cell B-cell lymphomas of the stomach) were developed.
Most informative morphological combinations were selected to differentiate 
MALT-lymphoma from neoplasias with a similar morphological pattern or  
reactive lymphoid infiltration. Tumor cell size was considered the most impor-
tant morphological criterion in tumor tissue analysis: the larger the tumor cells, 
the greater the changes in their cytomorphological appearance involving nuclear 
shape, chromatin status and increased cytological atypia.
Potential value of frozen and paraffin section immunohistochemistry was 
assessed in the common and differential diagnoses of MALT-lymphoma. The immu-
nological diagnosis must be made basing on changes in immunoarchitecture if other 
immunological criteria are absent.
The consistent application of different treatment methods is the key to the 
success in treating this category of patients. Conservative anti-Helicobacter pylori 
therapy in the early stages in primary patients gives good results and is a strategy 
necessary to maintain adequate organ function and prevent the toxic effects of 
chemotherapy, which, in turn, is used in the progressive refractory course of the 
disease. New drugs and targeted agents open up the possibility of treating people 
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